Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare haematological malignancy
derived from the precursors of plamacytoid dendritic cells, with an aggressive clinical course …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically challenging
hematologic malignancy with dismal outcomes. With a median age of∼ 70 years, the …

Background Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive
hematologic cancer that is caused by transformed plasmacytoid dendritic cells that …

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized
by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other …

The objective of this study was to evaluate the clinical features, prognostic factors, and
efficacy of treatments in patients with blastic plasmacytoid dendritic cell neoplasm with a …

Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease
characterized by malignant proliferation of a contingent blastic plasmacytoid dendritic cell …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare disease that currently
lacks genomic and genetic biomarkers to assist in its clinical management. We performed …

We sought to clarify the role of high-dose chemotherapy followed by autologous
hematopoietic stem cell transplantation (auto-HSCT) and allogeneic hematopoietic stem cell …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy
with historically poor outcomes and no worldwide consensus treatment approach. Unique …

Patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) have a poor prognosis
with conventional chemotherapy. In the present study, we retrospectively analyzed the …